HERZLIYA, Israel and CALGARY, Canada, February 27, 2026
InnoCan Pharma Corporation announced that the U.S. FDA Center for Veterinary Medicine (CVM) has granted the company a third consecutive annual sponsor fee waiver for its LPT-CBD (liposomal cannabidiol) drug candidate, reinforcing regulatory recognition of its innovative veterinary pharmaceutical development program. The waiver, issued under the “significant barrier to innovation” provision, highlights continued FDA support for advancing novel animal drug technologies targeting chronic pain in dogs, a growing unmet need in veterinary medicine.
FDA Recognition Strengthens Veterinary Drug Innovation
The FDA CVM waiver applies to InnoCan’s LPT-CBD injectable therapy, a liposome-based drug delivery platform designed for controlled and prolonged release of cannabidiol. This marks the third consecutive year the company has received such recognition, underscoring the regulatory importance of innovation-driven veterinary drug development. The CVM evaluates sponsor fee waivers annually based on scientific progress and development potential, and InnoCan’s consistent approvals reflect strong alignment with regulatory expectations and advancement milestones. This continued FDA engagement demonstrates growing confidence in next-generation drug delivery systems for animal health, particularly those offering alternatives to conventional pain management therapies.
Clinical Evidence Supports Chronic Pain Treatment in Dogs
The LPT-CBD platform is being developed as a subcutaneous injectable treatment for chronic pain in dogs, particularly targeting osteoarthritis-related pain, one of the most prevalent conditions in veterinary care. Clinical data from a randomized, blinded, placebo-controlled crossover study demonstrated statistically significant pain reduction and improved well-being in treated animals compared to placebo.
Advertisement
These findings provide robust scientific validation of the therapy’s analgesic potential, positioning LPT-CBD as a promising non-opioid alternative for long-term pain management in companion animals. Additionally, the therapy offers convenience through once-monthly administration, addressing both compliance challenges and quality-of-life improvements for pets and owners.
Advancing Veterinary Pharma Under GxP and Regulatory Frameworks
From a cGxP perspective, this development highlights strong adherence to Good Laboratory Practice (GLP) in preclinical and clinical evaluations and alignment with regulatory requirements under FDA CVM oversight. The fee waiver mechanism itself reflects a regulatory pathway designed to encourage innovation while maintaining compliance standards. InnoCan’s liposomal delivery technology also introduces manufacturing and formulation considerations under GMP-like conditions, particularly for controlled-release biologically active compounds. The continued regulatory recognition supports the scalability and future commercialization potential of LPT-CBD, as the company advances toward broader clinical validation and potential New Animal Drug Application (NADA) pathways.
Growing Veterinary Market and Strategic Impact
The announcement comes at a time of rapid expansion in the global veterinary pharmaceutical market, driven by increasing pet ownership and demand for advanced therapeutic solutions. With an estimated 94 million U.S. households owning pets, the need for safe, effective, and innovative chronic pain treatments continues to rise. InnoCan’s technology addresses this demand by combining scientific innovation with practical treatment delivery, positioning the company to play a significant role in the future of animal health therapeutics. The FDA CVM’s continued support further strengthens the company’s strategic positioning in the competitive veterinary biotech landscape, reinforcing its commitment to delivering next-generation pharmaceutical solutions.
Source: InnoCan Pharma press release
